An unbiased molecular characterisation of peripartum cardiomyopathy identfies mast cell chymase as a new diagnostic candidate and therapeutic target

Peripartum cardiomyopathy (PPCM) is a rare form of acute heart failure that develops in women towards the end of pregnancy or early in the postpartum period. Despite clinical similarities to dilated cardiomyopathy of other etiologies (non-peripartum cardiomyopathy; NPCM), the molecular mechanisms driving PPCM remain poorly understood. To characterize disease-specific proteomic remodeling, we conducted deep proteomic profiling of heart tissue from PPCM patients, NPCM patients, and healthy organ donors.